This study is looking at how well a new medicine, divarasib, works and how safe it is for people with a specific type of lung cancer. The cancer is called non-small cell lung cancer (NSCLC) that is advanced or has spread to other parts of the body. It focuses on patients who have a gene change called KRAS G12C. Divarasib will be compared to other medicines called sotorasib or adagrasib, which are already used to treat this cancer.

To join the study, you need to have this specific lung cancer and have tried other treatments that didn’t work. You need to be in good enough health to participate, with a life expectancy of at least 12 weeks. Doctors will check your health to make sure you are a good fit.

• This study may require multiple visits to the hospital over a certain period.
• There might be some risks, like side effects from the medicine. Your doctor will discuss these with you.
• Participants might get compensated for their time and travel.

Talk to your doctor to see if this study might be a good option for you!